Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Methoxybenzoic Acid Ethyl Ester SCHEMBL203475 | 0.94 | CA1 (0.66) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| 4-Methoxybenzoic Acid Ethyl Ester SCHEMBL27605414 | 0.93 | CA1 (0.63) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| SCHEMBL8656770 | 0.93 | CA12 (0.68) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| SCHEMBL5612948 | 0.89 | MAPT (0.59) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| SCHEMBL2997359 | 0.89 | MAPT (0.59) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| SCHEMBL8059469 | 0.89 | CA1 (0.59) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| 4-Methoxybenzoic Acid Ethyl Ester SCHEMBL10937413 | 0.88 | CA1 (0.69) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| 4-Methoxybenzoic Acid Ethyl Ester SCHEMBL30129677 | 0.88 | MAPT (0.62) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| SCHEMBL8206092 | 0.88 | PRSS1 (0.62) | MAPTL3MBTL1MEN1KMT2ACYP1A2 | |
| SCHEMBL9923544 | 0.87 | CA12 (0.61) | MAPTL3MBTL1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119201-B2 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1501515-B1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1501515-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER PRODUCTS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003090752-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | MAPT 4575/4885L3MBTL1 2680/4885MEN1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.